RT Journal Article
T1 Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
A1 Resino, Salvador
A1 Larrú, Beatriz
A1 Bellón, Jose Maria
A1 Resino, Rosa
A1 De José, Maria Isabel
A1 Navarro, Marisa
A1 Léon, Juan Antonio
A1 Ramos, José Tomás
A1 Mellado, Maria José
A1 Muñoz-Fernández, Maria Angeles
K1 Recuento de Linfocito CD4
K1 Niño
K1 Preescolar
K1 Femenino
K1 Infecciones por VIH
K1 VIH-1
K1 Humanos
K1 Transmisión Vertical de Enfermedad Infecciosa
K1 Masculino
K1 Nelfinavir
K1 Carga Viral
K1 Terapia Antirretroviral Altamente Activa
AB BACKGROUNDAntiretroviral treatment (ART) in children has special features and consequently, results obtained from clinical trials with antiretroviral drugs in adults may not be representative of children. Nelfinavir (NFV) is an HIV-1 Protease Inhibitor (PI) which has become as one of the first choices of PI for ART in children. We studied during a 3-year follow-up period the effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children.METHODSForty-two vertically HIV-infected children on HAART with NFV were involved in a multicentre prospective study. The children were monitored at least every 3 months with physical examinations, and blood sample collection to measure viral load (VL) and CD4+ cell count. We performed a logistic regression analysis to determinate the odds ratio of baseline characteristics on therapeutic failure.RESULTSVery important increase in CD4+ was observed and VL decreased quickly and it remained low during the follow-up study. Children with CD4+ <25% at baseline achieved CD4+ >25% at 9 months of follow-up. HIV-infected children who achieved undetectable viral load (uVL) were less than 40% in each visit during follow-up. Nevertheless, HIV-infected children with VL >5000 copies/ml were less than 50% during the follow-up study. Only baseline VL was an important factor to predict VL control during follow-up. Virological failure at defined end-point was confirmed in 30/42 patients. Along the whole of follow-up, 16/42 children stopped HAART with NFV. Baseline characteristics were not associated with therapeutic change.CONCLUSIONNFV is a safe drug with a good profile and able to achieve an adequate response in children.
PB BIOMED CENTRAL LTD
YR 2006
FD 2006-07-11
LK http://hdl.handle.net/10668/1687
UL http://hdl.handle.net/10668/1687
LA en
NO Resino S, Larrú B, Maria Bellón J, Resino R, de José MI, Navarro M, et al. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children. BMC Infect. Dis. 2006; 6:107
NO Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 19, 2025